In a report released yesterday, Daina Graybosch from SVB Securities reiterated a Buy rating on LAVA Therapeutics (LVTX – Research Report), with a price target of $25.00. The company's shares closed last Wednesday at $3.64, close to its 52-week low of $3.22. According to TipRanks.com, Graybosch is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -26.2% and a 22.5% success rate. Graybosch covers the Healthcare sector, focusing on stocks such as Silverback Therapeutics, Werewolf Therapeutics, and Century Therapeutics. Currently, the analyst consensus on LAVA Therapeutics is a Moderate Buy with an average price target of $22.00.
https://www.tipranks.com/news/blurbs/lava-therapeutics-lvtx-gets-a-buy-rating-from-svb-securities?utm_source=advfn.com&utm_medium=referral
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more LAVA Therapeutics NV Charts.
LAVA Therapeutics NV (NASDAQ:LVTX)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more LAVA Therapeutics NV Charts.